Pharmaceutical management of gastroesophageal reflux disease - summary
Perras C, Otten N
Record ID 31999008083
English, French
Authors' objectives:
A study commissioned by CCOHTA entitled, 'Cost-effectiveness of alternative therapies for the long-term management of gastroesophageal reflux disease', evaluates different drug strategies used in the treatment of gastroesophageal reflux disease (GERD). Specifically, the study has two objectives: 1) to determine the most effective therapy for the treatment of acute esophagitis Grades II to IV; 2) to conduct clinical and economic evaluations of maintenance ranitidine compared to maintenance omeprazole and maintenance cisapride. This overview attempts to put the findings of the commissioned study into clinical perspective
Authors' recommendations:
Treatment of acute esophagitis:
1. There is no conclusive evidence as to which of the H2 antagonists results in superior healing rates.
2. The use of omeprazole results in better healing rates than ranitidine or cisapride.
3. Just treating the acute episode and not instituting maintenance therapy yields high recurrence rates.
Treatment strategies incorporating maintenance therapy:
1. Strategies with maintenance cisapride and maintenance ranitidine have comparable disease-free periods with similar costs.
2. Compared to maintenance ranitidine and maintenance cisapride, maintenance omeprazole is the most effective treatment with the longest disease-free period and the lowest recurrence rate. However, it will cost an additional 348 USD per patient per year for six more weeks without GERD compared to maintenance ranitidine.
3. Study limitations include the use efficacy data and expert opinions instead of effectiveness studies. Also, a Ministry of Health perspective is taken instead of a societal one.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
1996
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Cisapride
- Costs and Cost Analysis
- Esophagitis
- Ranitidine
- Gastroesophageal Reflux
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.